Arkolith/Insider Trading/PCSA/Form 4

Young David

Pres. Research & Development, DirectorProcessa Pharmaceuticals, Inc. (PCSA) · full profile →Form 4 · filed Jun 16, 2026
Net Buying
Open-Market Buys
$5K
Open-Market Sells
$0
Net Open-Market Flow
$5K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 15, 2026Buy(P)2K$2.22$5K19K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000897069-26-001414) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML